Loading…
5 companies · GEL, thousands · columns ordered by revenue
| Line item | Pulparmi | NS Georgia | Med Treideri | Anshen Pharma | Maksparma |
|---|---|---|---|---|---|
| Total Revenue | 3,653 | 2,369 | 2,262 | 1,830 | — |
| Total COGS | -3,026 | -1,309 | -1,338 | -879 | — |
| Gross Profit | 627 | 1,060 | 924 | 951 | — |
| Gross Margin | 17.2% | 44.8% | 40.9% | 52.0% | — |
| Total Operating Expenses | -939 | -627 | -715 | -340 | — |
| EBITDA | -312 | 433 | 210 | 611 | — |
| EBITDA Margin | -8.5% | 18.3% | 9.3% | 33.4% | — |
| Total D&A | -3 | -11 | -6 | 0 | — |
| EBIT / Operating Income | -315 | 422 | 203 | 611 | — |
| Profit Before Tax | -315 | 421 | 164 | 520 | — |
| Total Income Tax | 0 | -14 | 0 | 0 | — |
| Net Profit / (Loss) | -315 | 407 | 164 | 520 | — |
| Net Margin | -8.6% | 17.2% | 7.2% | 28.4% | — |
| Other Comprehensive Income | -6 | — | — | — | — |
| Total Comprehensive Income | -322 | — | — | — | — |
| Total Other Income | — | -1 | — | -92 | — |
| Total Interest Expense | — | — | -39 | — | — |
Not every picked company reports every selected year — FY2023: no filing for Maksparma. Those cells are left blank (no filing), not zero.
| Company | Sector | EBITDA margin · FY 2023 | Percentile | Sector n |
|---|---|---|---|---|
| Anshen Pharma | Pharma | 33.4% | 79th pct | 123 |
| NS Georgia | Pharma | 18.3% | 54th pct | 123 |
| Med Treideri | Pharma | 9.3% | 34th pct | 123 |
| Pulparmi | Pharma | -8.5% | 11th pct | 123 |
| Maksparma | Pharma | — | no FY data | 123 |
Percentile is within each company's own sector across the whole FY2023 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.